Isatuximab

What it is used for

SARCLISA is indicated:

• in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
• in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
• in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).

Side effects, and when to stop

The following clinically significant adverse reactions from SARCLISA are also described in other sections of the labeling:

• Infusion-Related Reactions
• Infections
• Neutropenia
• Second Primary Malignancies

Who should not take it

SARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients.

Storing it

Storage

Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. Do not shake.

Handling and Disposal

Discard unused portion of solution. All materials that have been utilized for dilution and administration should be disposed of according to standard procedures.